Cargando…

A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors

A critical requirement in neuroendocrine tumor (NET) management is a blood biomarker test that is sensitive, specific and reproducible. We evaluated a PCR-based 51-transcript signature to detect tumors, compared it with chromogranin A (CgA) and examined the confounding effect of proton pump inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales: Modlin, Irvin M, Aslanian, Harry, Bodei, Lisa, Drozdov, Ignat, Kidd, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473957/
https://www.ncbi.nlm.nih.gov/pubmed/25316294
http://dx.doi.org/10.1530/EC-14-0100
_version_ 1784575112930918400
author Modlin, Irvin M
Aslanian, Harry
Bodei, Lisa
Drozdov, Ignat
Kidd, Mark
author_facet Modlin, Irvin M
Aslanian, Harry
Bodei, Lisa
Drozdov, Ignat
Kidd, Mark
author_sort Modlin, Irvin M
collection PubMed
description A critical requirement in neuroendocrine tumor (NET) management is a blood biomarker test that is sensitive, specific and reproducible. We evaluated a PCR-based 51-transcript signature to detect tumors, compared it with chromogranin A (CgA) and examined the confounding effect of proton pump inhibitors (PPIs), which cause falsely elevated CgA levels. The multigene signature was evaluated in two groups. Group 1: 125 prospectively collected NETs: gastroenteropancreatic NETs (n=91, including 42 pancreatic and 40 small intestinal), carcinoids of unknown primary (n=18) and other sites (n=16). Group 2: prospectively collected non-NET patients receiving PPIs (>1 month; dyspepsia, n=19; GERD, n=6; and pancreatitis, n=4) and 50 controls. All samples were analyzed by PCR (marker genes) and ELISA (DAKO–CgA). Sensitivity comparisons included χ (2), non-parametric measurements, and receiver operating characteristic (ROC) curves. Group 1: 123 NETs were PCR-positive (98.4%) compared with 50 (40%) CgA-positive (χ (2)=97.3, P<10(−26)). Significant differences (P<0.001) were noted between pancreas: PCR 95% vs CgA 29.2% (P<10(−9)) and small intestine: 100 vs 58% (P<10(−4)). The multigene test was elevated in all grades (G1–G3), in both local and disseminated disease, and was not normalized by somatostatin analog therapy. It was also elevated in 97% of CgA normal NETs. Group 2: PPI administration increased CgA in 83% and CgA was elevated in 26% of controls. PCR values were not elevated in either group. PCR performance metrics were as follows: sensitivity 98.4%, specificity 100%, positive predictive value 100%, negative predictive value 97.8%, and the ROC-derived area under the curve (AUC) was 0.997. These were significantly better than CgA (all metrics <60%; AUC, 0.54; Z-statistic, 10.44, P<0.0001). A 51-panel multigene blood transcript analysis is significantly more sensitive than plasma CgA for NET detection and is unaffected by acid suppression therapy.
format Online
Article
Text
id pubmed-8473957
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-84739572021-10-01 A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors Modlin, Irvin M Aslanian, Harry Bodei, Lisa Drozdov, Ignat Kidd, Mark Endocr Connect Research A critical requirement in neuroendocrine tumor (NET) management is a blood biomarker test that is sensitive, specific and reproducible. We evaluated a PCR-based 51-transcript signature to detect tumors, compared it with chromogranin A (CgA) and examined the confounding effect of proton pump inhibitors (PPIs), which cause falsely elevated CgA levels. The multigene signature was evaluated in two groups. Group 1: 125 prospectively collected NETs: gastroenteropancreatic NETs (n=91, including 42 pancreatic and 40 small intestinal), carcinoids of unknown primary (n=18) and other sites (n=16). Group 2: prospectively collected non-NET patients receiving PPIs (>1 month; dyspepsia, n=19; GERD, n=6; and pancreatitis, n=4) and 50 controls. All samples were analyzed by PCR (marker genes) and ELISA (DAKO–CgA). Sensitivity comparisons included χ (2), non-parametric measurements, and receiver operating characteristic (ROC) curves. Group 1: 123 NETs were PCR-positive (98.4%) compared with 50 (40%) CgA-positive (χ (2)=97.3, P<10(−26)). Significant differences (P<0.001) were noted between pancreas: PCR 95% vs CgA 29.2% (P<10(−9)) and small intestine: 100 vs 58% (P<10(−4)). The multigene test was elevated in all grades (G1–G3), in both local and disseminated disease, and was not normalized by somatostatin analog therapy. It was also elevated in 97% of CgA normal NETs. Group 2: PPI administration increased CgA in 83% and CgA was elevated in 26% of controls. PCR values were not elevated in either group. PCR performance metrics were as follows: sensitivity 98.4%, specificity 100%, positive predictive value 100%, negative predictive value 97.8%, and the ROC-derived area under the curve (AUC) was 0.997. These were significantly better than CgA (all metrics <60%; AUC, 0.54; Z-statistic, 10.44, P<0.0001). A 51-panel multigene blood transcript analysis is significantly more sensitive than plasma CgA for NET detection and is unaffected by acid suppression therapy. Bioscientifica Ltd 2014-10-14 /pmc/articles/PMC8473957/ /pubmed/25316294 http://dx.doi.org/10.1530/EC-14-0100 Text en © 2014 The authors https://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Modlin, Irvin M
Aslanian, Harry
Bodei, Lisa
Drozdov, Ignat
Kidd, Mark
A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors
title A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors
title_full A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors
title_fullStr A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors
title_full_unstemmed A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors
title_short A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors
title_sort pcr blood test outperforms chromogranin a in carcinoid detection and is unaffected by proton pump inhibitors
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473957/
https://www.ncbi.nlm.nih.gov/pubmed/25316294
http://dx.doi.org/10.1530/EC-14-0100
work_keys_str_mv AT modlinirvinm apcrbloodtestoutperformschromograninaincarcinoiddetectionandisunaffectedbyprotonpumpinhibitors
AT aslanianharry apcrbloodtestoutperformschromograninaincarcinoiddetectionandisunaffectedbyprotonpumpinhibitors
AT bodeilisa apcrbloodtestoutperformschromograninaincarcinoiddetectionandisunaffectedbyprotonpumpinhibitors
AT drozdovignat apcrbloodtestoutperformschromograninaincarcinoiddetectionandisunaffectedbyprotonpumpinhibitors
AT kiddmark apcrbloodtestoutperformschromograninaincarcinoiddetectionandisunaffectedbyprotonpumpinhibitors
AT modlinirvinm pcrbloodtestoutperformschromograninaincarcinoiddetectionandisunaffectedbyprotonpumpinhibitors
AT aslanianharry pcrbloodtestoutperformschromograninaincarcinoiddetectionandisunaffectedbyprotonpumpinhibitors
AT bodeilisa pcrbloodtestoutperformschromograninaincarcinoiddetectionandisunaffectedbyprotonpumpinhibitors
AT drozdovignat pcrbloodtestoutperformschromograninaincarcinoiddetectionandisunaffectedbyprotonpumpinhibitors
AT kiddmark pcrbloodtestoutperformschromograninaincarcinoiddetectionandisunaffectedbyprotonpumpinhibitors